SubHero Banner

Farxiga® (dapagliflozin) – New indication

April 30, 2021 - The FDA announced the approval of AstraZeneca’s Farxiga (dapagliflozin), to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression.

Download PDF